Risk Stratification of New Persistent Left Bundle Branch Block After Transcatheter Aortic Valve Implantation.
Aortic Valve
/ surgery
Aortic Valve Stenosis
Bundle-Branch Block
/ epidemiology
Heart Failure
/ epidemiology
Humans
Pacemaker, Artificial
Retrospective Studies
Risk Assessment
/ methods
Stroke Volume
Transcatheter Aortic Valve Replacement
/ adverse effects
Treatment Outcome
Ventricular Function, Left
Journal
The American journal of cardiology
ISSN: 1879-1913
Titre abrégé: Am J Cardiol
Pays: United States
ID NLM: 0207277
Informations de publication
Date de publication:
15 07 2022
15 07 2022
Historique:
received:
29
11
2021
revised:
21
03
2022
accepted:
28
03
2022
pubmed:
22
5
2022
medline:
16
6
2022
entrez:
21
5
2022
Statut:
ppublish
Résumé
Previous studies reported that new-onset persistent left bundle branch block (NOP-LBBB) was related to worse outcomes after transcatheter aortic valve implantation (TAVI). However, these results can be confounded by the presence of permanent pacemaker (PPM) implantation before and after TAVI. Long-term outcomes and the risk stratification of NOP-LBBB not having PPM implantation before and after TAVI have not been fully investigated. This is an international, multicenter, retrospective study of patients who underwent TAVI from July 31, 2007, to May 8, 2020. A total of 2,240 patients were included, and 17.5% of patients developed NOP-LBBB. NOP-LBBB was associated with cardiac mortality (adjusted hazard ratio [aHR] 1.419, 95% confidence interval [CI] 1.014 to 1.985, p = 0.041) and the composite outcomes of cardiac mortality and/or heart failure readmission (aHR 1.313, 95% CI 1.027 to 1.678, p = 0.030). Patients who developed NOP-LBBB with pre-TAVI left ventricular ejection fraction (LVEF) <40% were significantly associated with cardiac mortality (aHR 2.049, 95% CI 1.039 to 4.041, p = 0.038), heart failure (aHR 3.990, 95% CI 2.362 to 6.741, p <0.001), and the composite outcome (aHR 2.729, 95% CI 1.703 to 4.374, p <0.001). Although NOP-LBBB with pre-TAVI LVEF >40% had a significant decrease in LVEF 6 to 12 months after TAVI (-1.8 ± 9.7% vs +0.6 ± 8.1%, p = 0.003), NOP-LBBB with pre-TAVI LVEF <40% had a significant increase in LVEF 6 to 12 months after TAVI (+9.7 ± 13.6% vs +13.0 ± 11.7%, p = 0.157). In conclusion, patients with NOP-LBBB without pre-TAVI and post-TAVI PPM developed significantly worse long-term outcomes, especially in patients with pre-TAVI LVEF <40%. Further prospective investigation should be undertaken.
Identifiants
pubmed: 35597627
pii: S0002-9149(22)00405-2
doi: 10.1016/j.amjcard.2022.03.053
pii:
doi:
Types de publication
Journal Article
Multicenter Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
80-87Informations de copyright
Copyright © 2022 Elsevier Inc. All rights reserved.